Sangamo Therapeutics (SGMO)
OTHER OTC:SGMO
Want to see SGMO full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.06Last Year’s EPS
-0.08Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call highlights meaningful clinical and regulatory progress for ST-920 (rolling BLA, FDA affirmation of 2-year confirmatory endpoint, durable long-term patient data) and continued advancement across neurology programs and platform technologies. However, material near-term risks center on capital availability and a NASDAQ delisting determination that forced a transition to the OTCQB market. Progress on regulatory and scientific fronts is balanced by significant financing and market-listing challenges that could impact execution and timing.Company Guidance
BLA Rolling Submission Progress for ST-920 (Fabry)
First 2 modules of the rolling BLA for ST-920 submitted; company states the rolling submission is ~3/5 complete and anticipates completing the BLA submission as early as this summer, subject to adequate funding. FDA affirmed accelerated approval pathway using mean annualized eGFR slope at 52 weeks across all 32 dosed patients.
Regulatory Clarity from FDA
FDA recently affirmed that 104-week (2-year) eGFR data can serve as confirmatory evidence and indicated an additional confirmatory study will not be required, potentially accelerating path to traditional approval if 104-week data are submitted.
Durability and Clinical Data Signals
Company reports durability of benefit: 4 patients beyond 5 years with supraphysiological alpha‑Gal levels and 17 patients off enzyme replacement therapy (ERT), some over 3 years off ERT; team reports safety profile remains remarkable.
Neurology and Other Pipeline Milestones
Six clinical sites activated for Phase I/II STAND study (ST-503 for small fiber neuropathy); GLP toxicology study for ST-506 (prion disease) completed and analysis ongoing; ongoing CTA-enabling activities and productive MHRA interactions.
Scientific Visibility and Platform Advances
3 abstracts accepted at ASGCT and 4 presentations at the WORLD Symposium; showcased advances in zinc finger epigenetic regulation (Nav1.7, prion disease) and Modular Integrase (MINT) technology with reported impressive targeted integration levels across cell types.
Clinical Data Presentation and Long-Term Follow-up
1-year clinical module already submitted; company notes processes underway to clean and analyze full 2-year data and mentions seeing patients with up to 5 years’ follow-up, supporting long-term durability claims.
SGMO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SGMO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2026 | $0.14 | $0.14 | 0.00% |
Mar 30, 2026 | $0.31 | $0.25 | -19.87% |
Nov 06, 2025 | $0.55 | $0.46 | -16.36% |
Aug 07, 2025 | $0.48 | $0.46 | -5.39% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Sangamo Therapeutics (SGMO) report earnings?
Sangamo Therapeutics (SGMO) is schdueled to report earning on Aug 11, 2026, After Close (Confirmed).
What is Sangamo Therapeutics (SGMO) earnings time?
Sangamo Therapeutics (SGMO) earnings time is at Aug 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SGMO EPS forecast?
SGMO EPS forecast for the fiscal quarter 2026 (Q2) is -0.06.